Correction to “New approaches in gene therapy for sickle cell disease, moving in vivo”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVirus-based gene therapy research · Hemoglobinopathies and Related Disorders · RNA Interference and Gene Delivery
Kent DG. New approaches in gene therapy for sickle cell disease, moving in vivo. HemaSphere. 2024;8:e43.
In paragraph 2, the final sentence included the text “…involves large granulocyte‐macrophage progenitor‐level virus protection…”, which was incorrect. This should have read “Therapies that might remove the in vitro component, which involves substantial good manufacturing practice virus production and extensive quality control regimens, would therefore be of great utility and the field of in vivo therapies has understandably garnered intense interest”.
We apologize for this error.